IMNN Stock News & Analysis | Latest Updates

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

(NASDAQ:IMNN) LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a pre-recorded presentation from the Company will be available on demand as a part of the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of IMUNON's management team will also be conducting in-person one-on-one meetings with investors September 8 - 10, 2025.

September 2, 2025Investor

IMNN News

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Imunon Says Gained Nasdaq Compliance

IMUNON's IMNN-001 Shows Overall Survival Benefit Across Ovarian Cancer Subgroups In Phase 2 OVATION 2 Study, With Gains In HRP And BRCA+ Patients, Favorable Safety Profile, And Simultaneous ASCO 2025 And Peer-Reviewed Publication Presentation In Gynecolog

Imunon Announces Closing of Up to $9.75M At-the-Market Private Placement Under Nasdaq Rules

IMUNON To Present Abstract Highlighting IMNN-001 Data Based On Immune Biomarker Analysis From Phase 2 OVATION 2 Study At ESMO Gynaecological Cancers Congress 2025

Reported Friday, IMUNON Announces Private Placement Of Up To $9.75M, Including $3.25M Upfront And Warrants For $6.5M

IMUNON To Present New Data From Phase 2 OVATION 2 Study Of IMNN-001, Investigational Therapy For Treatment Of Advanced Ovarian Cancer At 2025 ASCO Annual Meeting

IMUNON Announces Withdrawal Of Form S-1 Registration Statement; No Securities Have Been Sold In Connection With The Offering Described In The Registration Statement

D. Boral Capital Downgrades Imunon to Hold

IMUNON Announces Six-Month Data From Phase 1 Proof-Of-Concept Trial Of Its IMNN-101 NA Vaccine Platform; Says Its PlaCCine Platform 'demonstrates better durability and other advantages compared to mRNA vaccines'

D. Boral Capital Maintains Buy on Imunon, Lowers Price Target to $17

Imunon Q1 EPS $(0.28) Beats $(0.35) Estimate

Imunon's Earnings: A Preview

IMUNON Announces First Site Initiated For Phase 3 OVATION 3 Study Of IMNN-001 In Newly Diagnosed Advanced Ovarian Cancer

D. Boral Capital Maintains Buy on Imunon, Maintains $29 Price Target

IMUNON Announces Data From Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 In Combination With Neoadjuvant Chemotherapy In Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer. Will Be Published In Gynecologic Oncology

Imunon Announces That An Abstract Highlighting New Overall Survival Data From Phase 2 Ovation 2 Study Of Imnn-001 To Treat Women With Newly Diagnosed Advanced Ovarian Cancer Was Accepted For Oral Presentation at the 2025 American Society of Clinical Oncol

HC Wainwright & Co. Reiterates Buy on Imunon, Maintains $14 Price Target

D. Boral Capital Maintains Buy on Imunon, Maintains $29 Price Target

D. Boral Capital Maintains Buy on Imunon, Maintains $29 Price Target

Imunon FY 2024 GAAP EPS $(1.62) Beats $(1.69) Estimate. Cash And Equivalents $5.9M

CORRECTION: Imunon Announces Phase 1 Trial Results For IMNN-101 DNA Vaccine Showing 2-4x Antibody Increase Vs. Omicron Variant With No Serious Adverse Effects In 24 Participants; Vaccine Demonstrated Cross-Reactivity With New Variants

CORRECTION: Imunon Announces Phase 1 Trial Results For IMNN-101 DNA Vaccine Showing 2-4x Antibody Increase Vs. Omicron Variant With No Serious Adverse Effects In 24 Participants; Vaccine Demonstrated Cross-Reactivity With New Variants

D. Boral Capital Maintains Buy on Imunon, Maintains $29 Price Target

IMUNON Announces 20% Increase In IL-12 Levels In Phase 2 OVATION 2 Study Of IMNN-001 For Advanced Ovarian Cancer; Phase 3 Trial Planned

HC Wainwright & Co. Reiterates Buy on Imunon, Maintains $12 Price Target

D. Boral Capital Maintains Buy on Imunon, Maintains $29 Price Target

IMUNON Announces FDA Alignment On CMC Strategy For IMNN-001 In Advanced Ovarian Cancer, Phase 3 Trial Set To Begin Q1 2025 With cGMP Manufacturing Process And Potency Assay Approved For Clinical And Commercial Use

EF Hutton Maintains Buy on Imunon, Maintains $29 Price Target